[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Arkansas Children's Hospital Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":577},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,40,69,107,139,168,191,216,251,278,303,327,352,379,401,419,447,469,487,507,530,553],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100642413","mitochondrial-energy-metabolism-in-burns-100642413",false,"NCT07643545","Mitochondrial Energy Metabolism in Burns","The Role of the Mitochondrian in the Metabolic Stress Response to Burn Trauma","Mito Burn","Inclusion Criteria:\n\n* Male or Female\n* Ages 2 years to 80 years\n* Requiring hospital admission for burn care\n* All races\n* All ethnicities\n\nExclusion Criteria:\n\n* Age \\\u003C 2 years\n* Under 10 kg in body mass\n* Age \\> 80 years\n* Active pregnancy\n* Unable to provide informed consent and no legal authorized representative present\n* Patient is considered moribund at the time of admission by the treating physician.","ALL","2 Years","80 Years",{"count":21,"type":22},125,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to assess the impact of burn injury on cellular energetics in patients that have been admitted to the burn center at Arkansas Children's Hospital for burn care and require one or more procedures to clean, debride, and repair burn wounds will be eligible to participate in this study.\n\nDuring the study, we will collect the following information:\n\n* General background information such as date of birth, height, weight, and other basic information.\n* Medical information, such as: basic medical information, details of burn injury, vital signs on the day of surgery, medicines you take during your stay, and some clinical tests.\n* Blood, urine, and tissue during surgeries you have during your stay.",[26],"Burn Injury","RECRUITING","2026-06-09",{"date":30,"type":31},"2026-06-11","ACTUAL",{"date":33,"type":31},"2023-04-20",{"date":35,"type":22},"2026-06",{"name":37,"class":38},"Arkansas Children's Hospital Research Institute","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100640043","a-prospective-assessment-of-bone-health-in-patients-with-severe-hemophilia-a-on-factor-viii-vs-factor-mimetic-prophylaxis-efa-emi-bone-health-study-100640043","NCT07582276","A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)","A Multi-institution Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)","Inclusion Criteria:\n\n1. The participant or legally authorized representative is willing and able to provide written informed consent.\n2. Diagnosis of severe hemophilia A (factor VIII activity \\\u003C 1%).\n3. Male sex.\n4. Age between 30 and 50 years (inclusive).\n5. BMI between 18.5 and 40 kg\u002Fm2\n6. The participant must have been on prophylaxis with Efanesoctocog alfa or Emicizumab for at least 3 months prior to enrollment and intend to remain on the current regimen for the next 5 years.\n7. Willingness to undergo all research procedures, including DEXA scans and the collection of blood samples.\n8. Willingness to complete all standard-of-care bleeding and treatment logs.\n\nExclusion Criteria:\n\n1. Unwillingness of the participant, parent, or legally authorized representative to provide informed consent.\n2. Diagnosis of a bleeding disorder other than or in addition to severe hemophilia A.\n3. Active Factor VIII inhibitors at the time of enrollment\n4. History of a disease known to influence bone metabolism unrelated to a bleeding disorder. (Examples: Paget's disease, osteogenesis imperfecta, Ehlers Danlos syndrome, Hyperparathyroidism)\n5. Past or present treatment with any anti-osteoporotic medication, excluding oral vitamin D or oral calcium supplements.\n6. Documented HIV infection or HCV infection (whether in progress or cured) at the cirrhotic stage.\n7. Presence of a non-removable metal device that would interfere with research procedures.\n8. Inability to tolerate a DEXA scan due to limited range of motion or body habitus.\n9. History of bone fractures or surgical repair within 8 weeks prior to enrollment.\n10. Participants with weight \\>300 pounds, due to limitations of DEXA scanner","MALE","30 Years","50 Years",{"count":51,"type":22},50,"This study will compare bone mineral density in patients with severe hemophilia A receiving prophylaxis with emicizumab or efanesoctocog alfa. Participants will undergo assessments of bone mineral density, bone remodeling biomarkers, thrombin generation, plasmin generation, and joint health over a five-year period. The study aims to evaluate whether differences in prophylactic therapy are associated with differences in bone health outcomes.",[54],"Hemophilia a",[56,57,58,59],"Bone Health","Emicizumab","Efanesoctocog alfa","hemophilia","NOT_YET_RECRUITING","2026-06-03",{"date":63,"type":31},"2026-06-04",{"date":65,"type":22},"2026-07-01",{"date":67,"type":22},"2032-08-01",{"name":37,"class":38},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100612320","phase-1-ruxolitinib-enhanced-haplo-hct-for-children-and-young-adults-with-sickle-cell-disease-100612320","NCT07252050","Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease","Ruxolitinib-Enhanced Conditioning for Pediatric and Young Adult Patients With Symptomatic Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation","RUX-HAPLO","Inclusion Criteria:\n\n1. Participants with any genotypic form of SCD aged 12 - 45 years at enrollment with ≥1 of the following:\n\n   1. History of stroke and\u002For vasculopathy, including evidence of asymptomatic cerebrovascular disease for pediatric patients.\n   2. Recurrent moderate-severe acute chest syndrome (ACS)\n   3. Recurrent vaso-occlusive pain episodes requiring parenteral analgesia despite the institution of supportive care.\n   4. Need for chronic transfusion therapy to prevent vaso-occlusive complications (i.e. pain, stroke, and ACS).\n   5. For adult patients, an echocardiographic finding of tricuspid valve regurgitant jet velocity (TRJV) ≥ 2.7 m\u002Fsec.\n2. Participants must have an HLA haploidentical first degree relative (parent, sibling, or half sibling) who is willing and able to donate bone marrow.\n3. Participants must meet institutional eligibility criteria for HCT.\n\nExclusion Criteria:\n\n1. Presence of an HLA-matched sibling who is willing and able to donate bone marrow.\n2. Uncontrolled infection, evidence of active TB, Hepatitis B or C infection, or HIV seropositivity or infection.\n3. Previous HCT or solid organ transplant.\n4. CNS revascularization procedure, myocardial infarction, pulmonary embolus or deep vein thrombosis in the past 6 months.\n5. Use of medications which significantly interfere with ruxolitinib metabolism.\n6. Known hypersensitivity or severe reaction to ruxolitinib or any component of the conditioning regimen or its excipients.\n7. Inability to swallow and retain oral medication (use of nasogastric or gastrostomy tube permitted).\n8. History of malignancy except resected basal cell carcinoma or treated carcinoma in-situ.\n9. Participation in another clinical trial involving an investigational or off-label use of a drug or device in the past 3 months.\n10. Currently pregnant or breast feeding.\n11. Clinically significant, uncontrolled autoimmune disease.\n12. High-titer anti-donor specific HLA antibodies (without review and approval by Study Chair).\n13. Participant (or guardian) inability or unwillingness to comply with the dose schedule and study evaluations, comprehend or sign informed consent and utilize a highly effective method of contraception (for participants of child-bearing potential).\n14. Any condition that would, in the investigator's judgment, interfere with full participation in the study, pose a significant risk to the subject, or interfere with interpretation of study data.","12 Years","45 Years",{"count":80,"type":22},24,"INTERVENTIONAL",[83,84],"PHASE1","PHASE2","This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD).\n\nThis study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.",[87,88,89,90,91],"Sickle Cell Disease","Hematopoetic Stem Cell Transplant","Haploidentical Hematopoietic Stem Cell Transplant","Haploidentical Stem Cell Transplantation","Graft Failure",[93,94,95,96,97,98],"Sickle cell disease","Hematopoietic cell transplant","Ruxolitinib","Pediatric","Young Adult","Haplo","2026-06-02",{"date":63,"type":31},{"date":102,"type":22},"2026-06-08",{"date":104,"type":22},"2029-11-19",{"name":37,"class":38},4,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":81,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100604378","phase-4-ensuring-access-to-optimal-therapy-in-cf-the-enact-study-100604378","NCT07148739","Ensuring Access to Optimal Therapy in CF: The ENACT Study","Ensuring Access to Optimal Therapy in Cystic Fibrosis: The ENACT Study","ENACT","Inclusion Criteria:\n\n* documentation of CF diagnosis per CFF diagnostic criteria and known CFTR genotype\n* age 2 years and older\n* ability to provide written informed consent and\u002For assent (by subject and\u002For legal guardian)\n* on a stable dose of triple combination CFTR modulator therapy for at least two weeks prior to Visit 1\n* clinically stable lung disease, defined as no documented acute decrease in FEV1 \\> 10%, OR use of additional antibiotics (intravenous \\[IV\\] or oral \\[PO\\]) within 4 weeks prior to screening\n\nExclusion Criteria:\n\n* recent significant unintentional weight loss, as determined by the investigator, in the 4 weeks prior to screening\n* pregnant or breastfeeding female\n* history of alcohol or substance abuse in the 6 months prior to screening\n* participation in a study involving an investigational intervention within 28 days (or 5 half-lives, whichever is longer) prior to screening\n* in the opinion of the Investigator, medical or psychiatric illness, or other conditions that would interfere with participation","3 Years",{"count":117,"type":22},100,[119],"PHASE4","This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).",[122],"Cystic Fibrosis (CF)",[124,125,126,127,128,129,130],"Cystic Fibrosis","CF","CFTR modulator","Pediatric CF patients","Elexacaftor","Tezacaftor","Ivacaftor","2026-05-29",{"date":99,"type":31},{"date":134,"type":31},"2025-06-10",{"date":136,"type":22},"2030-12",{"name":37,"class":38},3,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":81,"phases":149,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},"100581297","level-up-the-combined-and-independent-effects-of-exercise-training-and-dietary-enhancement-on-cardiometabolic-health-in-adolescents-with-obesity-100581297","NCT06848478","Level Up! (The Combined and Independent Effects of Exercise Training and Dietary Enhancement on Cardiometabolic Health in Adolescents With Obesity)","Inclusion Criteria:\n\n* Male or female aged 13 to 17 years.\n* Newly enrolled in a weight management program.\n* Excessive weight: Class I obesity I (≥95% percentile to \\\u003C 120% of the 95th percentile), class II Obesity (≥120 to \\\u003C140% of the 95th percentile, or BMI ≥35 to \\\u003C 40 g\u002Fm2).\n* Less than 60 min\u002Fday of moderate to vigorous physical activity.\n* Fruit intake ≤ 1.5 cup equivalent per day.\n* Vegetable intake ≤ 1.5 cup equivalent per day.\n* Medical release.\n\nExclusion Criteria:\n\n* Type 2 diabetes mellitus.\n* Asthma that requires daily use of inhalers to keep symptoms under control.\n* Asthma that requires the use of rescue inhalers (e.g., albuterol) \\>2 days per week\n* Exercise-induced asthma.\n* Autism spectrum disorder (e.g., Autistic disorder, Rett disorder, Asperger disorder, childhood disintegrative disorder, pervasive developmental disorder not otherwise specified (PDD-NOS).\n* Epilepsy.\n* Cancer.\n* Chronic kidney disease.\n* Hormonal disease (e.g., hypothyroidism and growth hormone deficiency).\n* Autoimmune diseases (e.g., lupus, thyroiditis, juvenile idiopathic arthritis).\n* Bleeding disorders (e.g., hemophilia).\n* Chronic infections (e.g., HIV, hepatitis B, hepatitis C).\n* Other pre-existing medical conditions or medications as determined by the investigators to affect the outcomes of interest.\n* Pregnancy.\n* Dislike of \\> 1 study product assessed at the initial visit.\n* Parent\u002Fchild refusal to have blood drawn.\n* Refusal to authorize study investigators to access data from the clinical records.","13 Years","17 Years",{"count":148,"type":22},120,[150],"NA","The goal of this clinical trial is to learn how exercise and diet quality affect the health of adolescents with obesity. The main questions it aims to answer are:\n\n* Does exercise improve cardiometabolic health in adolescents with obesity?\n* Does enriching the diet with fruits and vegetables improve cardiometabolic health in adolescents with obesity?\n* Do exercise and a fruit and vegetable diet together provide greater health benefits than either one alone in adolescents with obesity?\n\nResearchers will compare four groups to see how exercise and diet impact health:\n\n* Standard Care Group: Receives the usual care for obesity.\n* Exercise Group: Receives weekly exercise coaching and participates in a 12-week exercise program.\n* Diet Group: Receives weekly dietary coaching and eats a diet enriched with fruits and vegetables for 12 weeks.\n* Combined Exercise and Diet Group: Receives both exercise and dietary programs, namely weekly exercise and dietary coaching, participation in a 12-week exercise program, and daily consumption of fruits and vegetables for 12 weeks.\n\nDuring the 12-week study, participants will attend three study visits to:\n\n* Provide blood, stool, and urine samples.\n* Answer questions about health, sleep, diet, and physical activity.\n* Undergo body scans to measure fat, lean, and bone mass.\n* Complete blood vessel function and liver fat content assessments.\n* Assess resting exergy expenditure.\n* Complete fitness tests.\n* Wear a fitness tracker to monitor physical activity and sleep patterns.",[153],"Obesity",[155,156,157,158],"exercise","obesity","diet","cardiometabolic","2026-04-22",{"date":161,"type":31},"2026-04-24",{"date":163,"type":22},"2026-06-01",{"date":165,"type":22},"2029-03-31",{"name":37,"class":38},2,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":176,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":81,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":5},"100497900","comparison-of-uncomplicated-candidemia-therapy-duration-in-children-100497900","NCT05763251","Comparison of Uncomplicated Candidemia Therapy Duration in Children","Short Course Versus Standard Course Antifungal Therapy for Uncomplicated Candidemia in Children and Adolescents: A Multi-Center Randomized Controlled Trial","COUNT","Inclusion Criteria:\n\n1. Age \\> 120 days at the time of the first negative blood culture at any participating site;\n2. Candidemia with at least one positive blood culture for any Candida spp;\n3. Receiving\u002Freceived an echinocandin (caspofungin, micafungin, anidulafungin, or rezafungin) as primary antifungal therapy for candidemia for at least 2 days from day of first negative culture with continuation of uninterrupted systemic antifungal therapy at the time of enrollment);\n4. Sustained clearance of Candida spp. defined as negative blood culture(s) obtained after onset of candidemia and before day of randomization;\n5. Partial or complete clinical response, as defined by published guidelines (Table 5), on or before day of randomization;\n6. Between the onset of qualifying candidemia and randomization, no suspicion of disseminated candidiasis by patient's clinical team or, if deemed clinically necessary, documented negative radiological imaging such as an abdominal ultrasound or abdominal CT scan.\n\nExclusion Criteria:\n\n1. Already receiving antifungal therapy for a previously diagnosed systemic invasive fungal disease;\n2. Neutropenic (absolute neutrophil count \\\u003C 500 cells\u002Fµl) at the time of enrollment or anticipated to be neutropenic in the week following randomization;\n3. Have an underlying condition that requires them to be on antifungal prophylaxis when not receiving directed therapy for an invasive fungal disease;\n4. Previous enrollment in this trial;\n5. Females of childbearing age with a current pregnancy diagnosis or without a negative pregnancy test for their current admission;\n6. A documented DNR order;\n7. Have an implantable cardiac device (e.g., ventricular assist device, pacemaker)","120 Days",{"count":178,"type":22},420,[150],"The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are:\n\n* Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy.\n* Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups.\n\nParticipants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.",[182],"Invasive Candidiasis","2026-04-15",{"date":185,"type":31},"2026-04-17",{"date":187,"type":31},"2023-09-08",{"date":189,"type":22},"2032-06-30",{"name":37,"class":38},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":198,"sex":199,"minAge":200,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":39},"100629625","longitudinal-prospective-study-of-maternal-and-child-nutrition-in-arkansas-100629625","NCT07477106","Longitudinal Prospective Study of Maternal and Child Nutrition in Arkansas","Longitudinal Prospective Study of Maternal and Child Nutrition in Arkansas - The Thrive Study","Inclusion Criteria:\n\n* At least 30 weeks pregnant\n* Ability to engage in study procedures throughout the first 12 months postpartum\n\nExclusion Criteria:\n\n* None",true,"FEMALE","18 Years",{"count":21,"type":22},"The investigators want to learn how women's diets may impact breastfeeding outcomes. This study will help the investigators learn more about how diet and social factors like food access may impact mothers' health, breastfeeding, and their baby's health. Participants will attend a visit before birth, then 11 visits as their baby grows up. All visits will be remote using RedCap, phone or video call, text messaging or any other communication modalities of preference to the participant. The investigators will ask for personal information about participants' family, home, and finances, health literacy, medical history, current medications, pregnancy complications, mental health (depression, quality of life), confidence in breastfeeding, eating habits, and plan to feed their baby. After childbirth, the investigators will ask about participants' delivery and child's health, and request access to their child's medical records. Across all visits, the investigators will ask participants to measure their weight, height, blood pressure, activity and sleep, and child's length; the investigators will also ask them to ship urine, stool, and breast milk samples. The investigators will obtain a 24-hour feeding log for the child, as well as a log of what the mother ate and drank over 24 hours.",[204,205,206,207],"Maternal Nutrition","Infant Nutrition","Pediatric Nutrition","Maternal Health","2026-03-13",{"date":210,"type":31},"2026-03-17",{"date":212,"type":22},"2026-05",{"date":214,"type":22},"2029-06",{"name":37,"class":38},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":224,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":228,"conditions":229,"keywords":238,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":167},"100625415","a-multi-site-study-to-evaluate-the-persistence-of-protective-immunity-to-routine-childhood-vaccinations-in-participants-with-b-allly-who-have-received-blinatumomab-100625415","NCT07422337","A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL\u002FLy Who Have Received Blinatumomab","Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination","BOOSTER","Inclusion Criteria:\n\n* Diagnosis of B-lineage acute lymphoblastic leukemia\u002Flymphoma\n* ≥1 year old and up to 21 years old at diagnosis\n* Informed consent provided, and if applicable, child assent provided\n* Must have received all vaccinations routinely administered during first year of life\n\nExclusion Criteria:\n\n* Relapsed\u002Frefractory disease at any time\n* Received or will require a bone marrow transplant and\u002For cellular therapy\n* Pregnancy","1 Year","23 Years",{"count":227,"type":22},300,"The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia\u002FLymphoma. The main study aims are:\n\n* Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL\u002FLy who have received blinatumomab.\n* To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity.\n\nResearchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.",[230,231,232,233,234,235,236,237],"B-Cell ALL","B-Cell Acute Lymphoblastic Leukaemia","B-Cell Lymphoblastic Leukemia","B-Cell Lymphoblastic Leukemia\u002FLymphoma","B-cell Acute Lymphoblastic Leukemia (B-ALL)","B-cell Acute Lymphoblastic Leukemia","B-cell Childhood Acute Lymphoblastic Leukemia","B-cell Leukemia",[239,240,241,242],"vaccines","cancer","blinatumomab","immunotherapy","2026-02-23",{"date":245,"type":31},"2026-02-25",{"date":247,"type":31},"2026-01-13",{"date":249,"type":22},"2029-01",{"name":37,"class":38},{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":81,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":39},"100619567","we-move-with-windy-gross-motor-development-for-early-childhood-100619567","NCT07346300","We-Move With Windy: Gross Motor Development for Early Childhood","Pediatric Physical Activity: Tailored Intervention for Children Born to Mothers With Obesity","Inclusion Criteria: Mother-child pair where the mother has\n\n* Body mass index \\>30 and\n* The child is between 3 and 5 years of age.\n\nExclusion Criteria:\n\n* mothers sharing that a doctor has requested that either mother or child not exercise (e.g., asthma).",{"count":259,"type":22},266,[150],"The long-term goal of this project is to learn whether a tailored physical activity program is practical, enjoyable, and helpful for families, and whether it has the potential to improve children's physical development and health. Before launching a large study, the research team completed several early phases to make sure the program met families' needs. First, a needs assessment was conducted with mothers to understand barriers to physical activity and what types of support would be most useful. Using this feedback, the program was refined and tested with three mother-child pairs over six weeks. Finally, there was an 18-week pilot randomized trial to examine feasibility and acceptability.\n\nResearchers are now conducting a larger randomized trial with up to 266 families. Half of the families are randomly assigned to receive the physical activity program, and half to a comparison group. The program combines fun, age-appropriate movement activities for children with practical support for parents. Sessions focus on building core movement skills such as jumping, balancing, running, and throwing, while also encouraging confidence, coordination, and enjoyment of being active. Activities can be adapted to each child's ability and home environment, making the program realistic for busy families.\n\nThe program includes both in-person sessions and technology-based activities. In-person sessions provide hands-on support for learning new skills. Technology-based activities offer simple ideas families can use at home or during daily routines, such as hopping games, balance challenges, or quick movement breaks.\n\nBecause parents in earlier phases wanted nutrition support, in-person sessions also includes a brief, child-friendly exposure to fruits and vegetables, along with simple recipes. A \"Tasting Party\" at the start of the program allows children to try different foods, and Veggie Meter scans at the beginning and end of the study help track changes in fruit and vegetable intake.\n\nOverall, this study will help determine whether a family-tailored physical activity program is a promising approach to improving physical activity, movement skills, and early health indicators in young children born to mothers with obesity.",[263],"Physical Activities",[265,266,267,268,269],"Preschool children","Early childhood","Physical activity intervention","Gross motor skills","Motor development","2026-01-21",{"date":272,"type":31},"2026-01-22",{"date":274,"type":31},"2025-07-28",{"date":276,"type":22},"2031-07-01",{"name":37,"class":38},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":199,"minAge":200,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":81,"phases":287,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":302,"locationsCount":39},"100619367","community-expecting-exercise-during-pregnancy-100619367","NCT07343700","Community Expecting: Exercise During Pregnancy","Community Expecting: Exercise During Pregnancy for Sedentary Women With Obesity","Inclusion Criteria:\n\n* 18 years of age or older\n* Having a BMI ≥ 30\n* Not currently meeting guidelines for 150 min of moderate physical activity per week.\n* All children born to mother participants will be included and eligible.\n\nExclusion Criteria:\n\n* Non-English speaking individuals.\n* Contraindications for exercise (preeclampsia-eclampsia, premature rupture of the membranes, antepartum hemorrhage, placenta previa, or multiple gestation),) as determined by the investigators to affect the outcomes of interest\n* Using recreational drugs, tobacco, or alcohol during their pregnancy.\n* \\\u003C 11 or \\> 16 weeks gestation",{"count":286,"type":22},228,[150],"Regular physical activity during pregnancy is safe and offers many health benefits for both mothers and their babies. Research over the past decade shows that exercise can help pregnant women gain a healthy amount of weight, lower their risk of gestational diabetes and high blood pressure, and reduce stress, anxiety, and symptoms of postpartum depression. Babies also benefit when their mothers are active, with lower risks of preterm birth, unhealthy birth size, and childhood obesity.\n\nDespite this strong evidence, very few exercise programs for pregnant women have been tested in real-world community settings, such as fitness centers, community health programs, or local organizations. Even fewer studies explain how these programs were delivered or what helped them succeed. Without this information, it is difficult for communities and health programs to offer exercise support that is both effective and practical for pregnant women.\n\nTo address this gap, the research team adapted an evidence-based program called EXPECTING so it could be delivered by community organizations. Previous participants and community advisors helped to understand what changes were needed to make the program easier to offer while still keeping it safe and effective. The core parts of the program, including the type, amount, and intensity of aerobic and strength-building exercises, remained the same and are based on established pregnancy exercise guidelines.\n\nThe adapted program, called COMMUNITY EXPECTING, includes both aerobic exercise and resistance training. The research team also developed specific supports to help community instructors deliver the program consistently and with confidence. All program components have already been tested in community settings and shown to be realistic, acceptable, and delivered as planned.\n\nThis study will examine whether offering a structured exercise program in community settings helps pregnant women be more physically active than usual prenatal care alone. We will also assess whether the program can be delivered successfully and in a way that works for both participants and community providers. The results will help determine whether COMMUNITY EXPECTING is a practical approach for supporting healthy pregnancies in real-world settings.",[263],[291,292,293,294,295],"Pregnancy","Prenatal Exercise","Prenatal fitness","Community","Implementation","2026-01-08",{"date":298,"type":31},"2026-01-15",{"date":300,"type":31},"2025-05-30",{"date":276,"type":22},{"name":37,"class":38},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":198,"sex":17,"minAge":311,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":81,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":39},"100406516","protein-requirements-for-active-children-100406516","NCT04573439","Protein Requirements for Active Children","Children's Protein Requirements With Physical Activity: The ChiPP Study","ChiPP","Inclusion Criteria:\n\n* Inclusion Criteria\n\n  * Boys or girls\n  * Ages 8-10 years\n  * All races\n  * All ethnicities\n  * Children who were determined to have normal weight (BMI \\\u003C85th percentile) already determined under Mitochondria (MI) Energy (IRB Protocol: 260376)\n  * Participants willing to stop taking nutritional supplements (e.g., multivitamins, vitamin D, fish oil, probiotics, prebiotics, immune boosters, and others) for at least 2 weeks prior to each study testing visit\n  * Children without an infection requiring antibiotics willing to be rescheduled after at least 2 months of finalizing antibiotic treatment.\n  * Children without viral infections such as diarrhea, cold, or flu willing to be rescheduled after at least 2 weeks of resolution of symptoms.\n  * Children determined sedentary or active, based on both peak oxygen uptake (VO2) and accelerometer data, as described below: Children who completed a peak fitness test during MI Energy (IRB Protocol: 260376), and for whom peak VO2 data are as follows:\n\nPeak ⩒O2, ml·min-1·fat free mass index (FFMI)-1 Boys Girls Boys Girls\n\n* 89 ≤ 80 ≥115 ≥105 FFMI, fat-free mass index\n\nAND\n\nChildren who completed accelerometer measures during MI Energy (IRB Protocol: 260376), and for whom average daily activity counts and\u002For minutes of moderate to vigorous physical activity are as follow:\n\nSedentary Active Activity counts\u002Fday \\\u003C2,924,494 ≥3,767,075 Minutes of Moderate to vigorous physical activity\u002Fday \\\u003C60 ≥60\n\nChildren who completed National Survey of Children's Health and Youth Risk Behavior Survey (NSCH-YRBS) questionnaire during MI Energy study (IRB Protocol: 260376). Children who report ≥3 hours\u002Fday of Television (TV) (Sedentary) or ≤2 hours\u002Fday of TV (Active) will be considered\n\n* Children who completed Dual-energy x-ray absorptiometry (DXA) measures during MI Energy study (IRB Protocol: 260376)\n* Children whose parents consented to the following in the MI Energy study (IRB Protocol: 260376): o A) be contacted about future follow-up studies to MI Energy, and having the data that is collected about their child in MI Energy being used also in these follow-up studies; and\n\n  * B) information collected in the MI Energy study may be used in future research related to bioenergetics (for example, blood cell mitochondria function), nutrition, obesity, cardiovascular health, or development; and\n  * C) any biological samples collected in the MI Energy study may be used in future research related to bioenergetics (for example, blood cell mitochondria function), nutrition, obesity, cardiovascular health, or development.\n\nExclusion Criteria:\n\n* • Participants who have been excluded from participation in the study MI Energy (IRB Protocol: 260376)\n\n  * Participants whose parents report any change in medical history that may potentially affect participation and\u002For study outcomes as determined by PI\n  * Weight loss \\>3 kg in last 6 months\n  * Taking medications that knowingly influences protein metabolism\n  * Phenylketonuria","8 Years","10 Years",{"count":314,"type":22},30,[150],"There is reason to believe the current dietary reference intakes for dietary protein for children are too low. Furthermore, children with high levels of physical activity and fitness may require a higher requirement. To better understand the protein requirements in minimally and highly physically fit and active children 8-10 y old, investigators will use the indicator amino acid oxidation technique.",[318],"Healthy","2025-12-22",{"date":321,"type":31},"2025-12-30",{"date":323,"type":31},"2021-08-16",{"date":325,"type":22},"2026-07",{"name":37,"class":38},{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":198,"sex":17,"minAge":311,"maxAge":77,"enrollmentInfo":333,"targetDuration":4,"studyType":81,"phases":335,"briefSummary":336,"conditions":337,"keywords":343,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":167},"100515529","the-sweet-kids-study-stevia-on-weight-and-energy-effect-over-time-100515529","NCT05992688","The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)","Inclusion Criteria\n\n* Age 8-12 years\n* Normal weight: BMI percentile ≥5th to \\\u003C85th\n* Excessive weight: BMI percentile ≥ 85th and \\\u003C140% of the 95th percentile or BMI ≥35 to \\\u003C40 kg\u002Fm2\n* Current consumption of sugar sweetened beverages (≥2 times \u002Fwk)\n* Low consumption of non-nutritive sweeteners (≤ 3 time\u002Fwk)\n* Willingness to consume experimental products Exclusion Criteria\n* Children with class 3 obesity (i.e., BMI ≥ 140% of the 95th percentile or BMI ≥ 40.0 kg\u002Fm2)\n* Dislike of experimental beverage taste (assessed at initial visit)\n* Asthma that requires daily use of inhalers to keep symptoms under control.\n* Asthma that requires use of rescue inhalers (e.g., albuterol) \\>2 days per week\n* Exercise induced asthma.\n* Autism spectrum disorder (e.g., Autistic disorder, Rett disorder, Asperger disorder, childhood disintegrative disorder, pervasive developmental disorder not otherwise specified (PDD-NOS).\n* Attention deficit hyperactivity disorder (ADHD) currently under medication.\n* Oppositional defiant disorder (ODD).\n* Epilepsy.\n* Cancer.\n* Chronic kidney disease.\n* Endocrine disorder (e.g., hypothyroidism and growth hormone deficiency).\n* Autoimmune diseases (e.g., lupus, thyroiditis, juvenile idiopathic arthritis)\n* Bleeding disorders (e.g., hemophilia)\n* Chronic infections (e.g., HIV, hepatitis B, hepatitis C).\n* Mental health disorders (e.g., depression and anxiety).\n* Type 2 and type 1 diabetes mellitus.\n* Other pre-existing medical conditions or medications as determined by the investigators to affect the outcomes of interest.\n* If, during the screening or consent process, the parent or child expresses refusal to have blood drawn. However, participants may remain in the study if after initially agreeing to the blood draw and enrolling they change their minds and choose not to allow blood draws or if blood draws are unsuccessful.\n* Dislike of study products assessed at initial visit.\n* Fasting glucose ≥126 mg\u002Fdl at enrollment.\n* Fasting A1C ≥6.5% at enrollment\n* Less than 2 months since completion of antibiotics",{"count":334,"type":22},150,[150],"This is an 8 to14-week three-arm randomized controlled in children 8 to 12 years old.\n\nThe main purpose of the study is to evaluate if stevia has benefits for weight control and metabolic function relative to caloric sweeteners, and whether it provides benefits in this regard similar to water.",[338,339,340,341,342],"Adiposity","Insulin Sensitivity","Weight Gain","Blood Pressure","Lipoproteins",[344],"Cardiometabolic health","2025-12-16",{"date":319,"type":31},{"date":348,"type":31},"2023-09-19",{"date":350,"type":22},"2026-11-30",{"name":37,"class":38},{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":199,"minAge":200,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":81,"phases":362,"briefSummary":363,"conditions":364,"keywords":368,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":167},"100587492","effect-of-prenatal-and-postnatal-intervention-strategies-on-breastfeeding-outcomes-in-women-with-excessive-weight-ready-set-nourish-study-100587492","NCT06929091","Effect of Prenatal and Postnatal Intervention Strategies on Breastfeeding Outcomes in Women With Excessive Weight (Ready, Set, Nourish Study)","Ready, Set, Nourish Study","RSN","Inclusion Criteria\n\n* Age 18 or older\n* Less than 37 weeks of pregnant with singleton fetus\n* Pre-pregnancy excessive weight (Body Mass Index ≥ 25 kg\u002Fm2)\n* Interested in breastfeeding\n* Willing to express colostrum from around 37 weeks of pregnancy if randomized to the prenatal intervention group\n* Willing to express human milk for sample collection during a 24-hour period\n* Willing to adhere to a meal plan for 5.5 months post-partum if randomized to the postnatal intervention group\n* Able to engage in study procedures for the first 24 months postpartum\n* Reside in Central Arkansas region Exclusion Criteria\n* Pre-existing conditions (e.g. diabetes, hypertension, heart disease, thyroid disorders);\n* Use of recreational drugs, tobacco, or 2 or more servings of alcohol per month\n* Food allergies, intolerances, or preferences interfering with the meal plan\n* Medical history including any contraindication to breastfeeding (medications or supplements incompatible with breastfeeding, substance use)Multiparous pregnancy\n* History of breast surgery or radiation\n* Congenital defects\n* Preeclampsia",{"count":361,"type":22},240,[150],"This study is about preparing women with excessive weight to have better breastfeeding outcomes. By doing this study, the investigators hope to learn more about how hand expression of breast milk or colostrum during pregnancy can help prepare a mother to breastfeed after she has her baby and about how her diet affects the composition of her breast milk and her baby's growth and development.",[365,366,367],"Breastfeeding","Dietary Intervention","Milk Expression, Breast",[365,369,153,370],"Human Milk","Health Diet","2025-12-04",{"date":373,"type":31},"2025-12-10",{"date":375,"type":31},"2025-11-07",{"date":377,"type":22},"2029-12-01",{"name":37,"class":38},{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":200,"enrollmentInfo":385,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":400},"100481537","multi-center-molecular-diagnosis-and-host-response-of-respiratory-viral-infections-in-pediatric-transplant-recipients-100481537","NCT05550298","Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients","Recipient Inclusion Criteria\n\n* Less than 18 years at the time of anticipated transplant\n* Participant meets one of the following criteria:\n\n  1. scheduled to receive allogeneic hematopoietic cell transplant within 14 days of enrollment or\n  2. Scheduled to or received solid organ transplant within 7 days before or after enrollment\n* Participant is receiving care at the time of enrollment at one of the study participating institutions.\n* Parent\u002Fguardian willing and able to provide informed consent, and if appropriate, child willing and able to provide informed assent.\n\nDonor Inclusion Criteria\n\n* Donor for HCT recipient enrolled on the VIPER study.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\nRecipient Exclusion Criteria\n\nNone\n\nDonor Exclusion Criteria\n\n* Is not an HCT donor for a participant enrolled on the VIPER study.\n* Not available to provide pre-transplant research blood sample.",{"count":386,"type":22},2000,"The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT).\n\nPrimary Objective\n\nTo determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors.\n\nSecondary Objectives:\n\n* To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV\u002FPIV3\u002FHMPV\u002FSARS-CoV-2 through one-year post-transplant among survivors.\n* To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV\u002FPIV3\u002FHMPV\u002FSARS-CoV-2 through one-year post-transplant among survivors .",[389,390,391],"Hematopoietic Cell Transplant","Solid Organ Transplant","Respiratory Viral Infection","2025-09-29",{"date":394,"type":31},"2025-10-02",{"date":396,"type":31},"2022-12-13",{"date":398,"type":22},"2029-08",{"name":37,"class":38},27,{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":199,"minAge":200,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":81,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":418,"locationsCount":39},"100385393","community-translation-of-the-expecting-study-100385393","NCT04298125","Community Translation of the Expecting Study","Antenatal Factors Impacting Obesity and Metabolism in Children: Sub-objective 2D","Inclusion Criteria:\n\n* (a) Body Mass Index \\> 30,\n* (b) singleton pregnancy,\n* (c) between 11-15 weeks of pregnancy (at enrollment),\n* (d) Do not currently meet recommended guidelines of 150 min of activity per week\n* (e) cleared by physician\n\nExclusion Criteria:\n\n* (a) contraindications for exercise (preeclampsia-eclampsia, premature rupture of the membranes, antepartum hemorrhage, placenta previa, multiple gestation and other defined conditions)\n* (b) illicit drug use.",{"count":409,"type":22},60,[150],"The Expecting intervention as delivered in prior studies in a clinical setting is described in a previous approved IRB submission (Protocol 202954). The current project will seek to engage community stakeholders to translate Expecting to a community-delivered intervention and to test its acceptability, feasibility, and fidelity in a proof of principle study with 60 expecting mothers.",[413],"Pregnancy Related",{"date":394,"type":31},{"date":416,"type":31},"2021-07-16",{"date":35,"type":22},{"name":37,"class":38},{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":199,"minAge":200,"maxAge":78,"enrollmentInfo":426,"targetDuration":4,"studyType":81,"phases":428,"briefSummary":429,"conditions":430,"keywords":434,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":4},"100567289","continuous-glucose-and-e-monitoring-to-support-healthy-weight-gain-in-pregnancies---the-gem-study-100567289","NCT06666257","Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancies - The GEM Study","GEM","The formative phase (Phase I), classified as exempt by the institutional review board will seek participation from individuals meeting the following criteria:\n\n1. Currently pregnant or pregnant within the past 36 months.\n2. Community partners with relevant perspectives to inform recruitment, adaptation approaches and feasibility of the phase 2 pilot trial.\n\nClinical Trial (Phase 2)\n\nInclusion Criteria:\n\n* pregnant women less than 20 weeks of gestation at time of screening\n* 18-45 years of age\n* BMI of 25 - 40 kg\u002Fm-2\n* Expecting a singleton pregnancy\n* Smartphone and\u002For reliable internet access\n* Willing to be identifiable to other study participants in the study program .\n\nExclusion Criteria:\n\n* Smoker\n* Preexisting medical conditions that might be exacerbated by pregnancy (e.g., diabetes mellitus, chronic renal failure, hypertension, malignancies, seizure disorder, lupus, drug or alcohol abuse, serious psychiatric disorders)\n* Current mental health or eating disorder\n* Contraindication to exercise (OB\u002FGYN release is obtained prior to consent)\n* Conceived with assisted fertility treatments\n* Medications during pregnancy known to influence fetal growth (e.g., thyroid hormone, glucocorticoids, insulin, oral hypoglycemic agents)\n* Plans to move out of the state in the next 6 months following screening.",{"count":427,"type":22},16,[150],"This single-arm pilot study will evaluate the feasibility and acceptability of a remotely delivered behavioral lifestyle intervention, adapted from the SmartMoms framework, to promote health gestational weight gain in pregnant women with overweight and obesity. Twelve to sixteen participants will receive weekly virtual motivational interview sessions with trained health coaches, review their daily weight data, step count, and continuous glucose monitoring data, and tailored guidance on physical activity and nutrition. Educational content will be delivered electronically, with peer support provided through a closed online group. A simulated (mock) control arm will be created post hoc from existing records for preliminary comparisons; all enrolled participants will receive the intervention.",[431,432,433],"Pregnancies at Increased Risk for Excessive Gestational Weight Gain","Ecological Momentary Assessment and Intervention","Continuous Glucose Monitor",[291,153,435,436,437,438],"Continuous Glucose Monitoring","Ecological Momentary Intervention","Gestational Weight Gain","Overweight","2025-08-12",{"date":441,"type":31},"2025-08-15",{"date":443,"type":22},"2025-10-01",{"date":445,"type":22},"2026-07-30",{"name":37,"class":38},{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":198,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":454,"conditions":455,"keywords":457,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":167},"100576598","the-sweet-dreams-study---accuracy-of-sleep-trackers-in-children-100576598","NCT06787378","The Sweet Dreams Study - Accuracy of Sleep Trackers in Children","Inclusion Criteria:\n\n* Age 2 to \\\u003C18 years\n* All BMIs\n* Scheduled at PSDC for evaluation of obstructive sleep apnea, snoring, or noisy breathing during sleep.\n\nExclusion Criteria:\n\n* Known diagnosis of sleep disorder\n* Neurological disorders (e.g., epilepsy, cerebral palsy, etc.)\n* Autism spectrum disorder\n* Attention deficit hyperactivity disorder\n* Oppositional defiant disorder\n* Chronic kidney disease\n* Hormonal disease\n* Autoimmune diseases\n* Bleeding disorders\n* Chronic infections (e.g., HIV, hepatitis B)\n* Mental health disorders (e.g., depression, anxiety)\n* Liver disease (e.g. hepatitis)\n* Referral for evaluation of disorders other than obstructive sleep apnea, snoring, or noisy breathing during sleep.\n* Pre-existing medical conditions or medications as determined by the investigators to affect the outcomes of interest.\n* Refusal to authorize study investigators to access data from the polysomnography test conducted at the Arkansas Children's Hospital PSDC.",{"count":227,"type":22},"The study aims to evaluate the accuracy of sleep trackers in children aged 2 to less than 18 years. Children undergoing polysomnography, the gold standard for assessing sleep quality and duration, at Arkansas Children's Hospital may be eligible to participate. Participants will be asked to wear sleep trackers on the day of their sleep test. The data collected from the sleep trackers will be compared with the polysomnography results to determine the devices' accuracy.",[456],"Sleep",[458,459,460],"sleep","accelerometer","polysomnography","2025-03-31",{"date":463,"type":31},"2025-04-03",{"date":465,"type":31},"2025-03-01",{"date":467,"type":22},"2029-02-28",{"name":37,"class":38},{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":198,"sex":17,"minAge":311,"maxAge":312,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":39},"100395314","bioenergetic-phenotypes-and-cardiometabolic-health-100395314","NCT04427462","Bioenergetic Phenotypes and Cardiometabolic Health","Linking Bioenergetic Phenotypes in Circulating Cells with Cardiometabolic Health in School-age Children","MI Energy","Inclusion Criteria:\n\nAges 8-10 years Boys and girls All ethnicity All BMI\n\nExclusion Criteria:\n\nsevere persistent asthma exercise induced asthma autism spectrum disorder attention deficit hyperactivity disorder attention deficit disorder\n\n* Opposition defiant disorder\n* conduct disorder\n* epilepsy\n* chronic kidney disease\n* hormonal disease\n* autoimmune diseases\n* bleeding disorders\n* chronic infections\n* mental health disorder\n* Type 2 and Type 1 diabetes\n* Other pre-existing medical conditions or medications as determined by the investigators to affect the outcomes of interest",{"count":227,"type":22},"This research study is about how daily activities, behaviors, and fitness affect the health and function of blood cells and their mitochondria, which are the powerhouses of the cells. These small mitochondria inside the cells make energy, and are very important for the health of the body.",[318],"2025-02-05",{"date":482,"type":31},"2025-02-07",{"date":484,"type":31},"2020-09-01",{"date":35,"type":22},{"name":37,"class":38},{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":11,"sex":17,"minAge":493,"maxAge":494,"enrollmentInfo":495,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":39},"100294062","glowing-and-expecting-follow-up-100294062","NCT03108001","Glowing and Expecting Follow Up","Inclusion Criteria:\n\n* Former Glowing and Expecting study participants aged 5 to 14 years of age\n\nExclusion Criteria:\n\n* Participants who were dropped from the Glowing and Expecting studies.","5 Years","14 Years",{"count":496,"type":22},514,"This study will help us learn more about how a mother's health during pregnancy may influence her child's growth and development later in life.",[318],"2025-01-29",{"date":501,"type":31},"2025-01-31",{"date":503,"type":31},"2017-03-27",{"date":505,"type":22},"2031-03-01",{"name":37,"class":38},{"id":508,"slug":509,"hasResults":11,"nctId":510,"briefTitle":511,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":515,"conditions":516,"keywords":518,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":39},"100461314","use-of-nasal-nitric-oxide-testing-in-improving-primary-ciliary-dyskinesia-clinical-care-100461314","NCT05287022","Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care","Inclusion Criteria:\n\n* Individuals who are diagnosed with Primary Ciliary Dyskinesia OR\n* Individuals with abnormal PCD diagnostics (abnormal ciliary biopsy or PCD genetics) OR\n* Individuals with unexplained bronchiectasis OR\n* Individuals undergoing PCD diagnostic testing (ciliary biopsy, PCD genetic testing) or concern based on clinical symptoms (at least two of the following):\n\n  * Neonatal respiratory distress\n  * Organ laterality defects\n  * Year-round cough starting in first year of life or bronchiectasis on chest CT\n  * Year-round nasal congestion starting in first year of life or pansinusitis\n  * Multiple ear infections in the first two years of life with sequelae (e.g. ear tubes, chronic effusion, abnormal audiological exam)\n  * History of recurrent pneumonias (at least 2 in one year or more than 3 at any time)\n* Ability to provide consent for participation in study by the participants or guardian\n* Ability to perform the test\n* Age \\>= 2 years of age\n\nExclusion Criteria:\n\n* Individuals who are unable to understand the requirements of the study.\n* Individuals (or guardians) who are unwilling to provide consent.\n* Individuals who are unable to complete the testing\n* Recent history of sinus surgery (within four weeks) or bloody nose (within one week) of testing (they can be included at a later date)\n* Patients who are currently being treated (within one week) with antibiotics for sinusitis or respiratory symptoms (they can be included at a later date)\n* Age \\\u003C2 years of age","99 Years",{"count":334,"type":22},"this study is aiming at learning more about primary ciliary dyskinesia (PCD) and tests that are used to diagnose this condition. One purpose of this study is to measure the level of nitric oxide in the nasal passages and examine how often the results correlate with other tests currently done to make the diagnosis.",[517],"Primary Ciliary Dyskinesia",[519,520,521],"nNO","Diagnosis","PCD","2025-01-28",{"date":524,"type":31},"2025-01-30",{"date":526,"type":31},"2021-06-14",{"date":528,"type":22},"2030-06",{"name":37,"class":38},{"id":531,"slug":532,"hasResults":11,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":11,"sex":17,"minAge":176,"maxAge":537,"enrollmentInfo":538,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":552},"100349275","non-invasive-diagnosis-of-pediatric-pulmonary-invasive-mold-infections-100349275","NCT03827694","Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections","DOMINIC","Inclusion Criteria:\n\n* Males or females age \\> 120 days and \\\u003C 22 years at any participating site\n* Have at least one of the following conditions associated with a known high incidence of IFI: hematopoietic stem cell transplantation (HSCT), aplastic anemia, bone marrow failure, primary or acquired immune deficiency, or malignancy\n* New (last 96 hours) radiographic evidence of at least one of the following: at least one nodular lesion greater than or equal to 5 mm in size, a wedge-shaped and segmental or lobar consolidation, a cavitary lesion, a lesion with a halo sign, a lesion with a reverse halo sign, or a lesion with an air crescent sign\n* Prolonged neutropenia (absolute neutrophil count \\\u003C 500 cells\u002Fµl for a period of ≥ 5 consecutive days) in 30 days prior to and including the day of qualifying chest MRI or CT scan date OR currently receiving systemic therapy for acute or chronic graft-versus-host disease (GVHD) OR presence of neutrophil dysfunction because of underlying acquired or primary immune deficiency (e.g. chronic granulomatous disease) on the date of the qualifying chest MRI or CT scan\n* Subject consent or parental\u002Fguardian permission (informed consent) and if appropriate, child assent\n\nExclusion Criteria:\n\n* Weight \\\u003C3 kg, so as to not exceed 3 ml\u002Fkg in a single blood draw\n* Previous inclusion in this study","21 Years",{"count":539,"type":22},400,"This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).",[542,543],"Pulmonary Invasive Fungal Infections","Pulmonary Invasive Aspergillosis","2024-09-24",{"date":546,"type":31},"2024-09-25",{"date":548,"type":31},"2018-10-30",{"date":550,"type":22},"2026-12-31",{"name":37,"class":38},33,{"id":554,"slug":555,"hasResults":11,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":198,"sex":199,"minAge":145,"maxAge":537,"enrollmentInfo":560,"targetDuration":4,"studyType":81,"phases":562,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":39},"100506529","phase-4-intravenous-ketorolac-administration-to-attenuate-post-procedural-pain-associated-with-intrauterine-device-placement-100506529","NCT05875571","Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement","Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Patients requiring sedated IUD placement at Arkansas Children's Hospital\n\nExclusion Criteria:\n\n* Allergy to ketorolac or other NDSAID\n* Known history of renal impairment\n* History of GI bleeding of peptic ulcer disease",{"count":561,"type":22},18,[119],"Intrauterine devices (IUDs) are a popular form of long-acting reversible contraception, with a high efficacy rate and few side effects. The insertion procedure for IUDs can be uncomfortable and painful. Sedation may be needed to improve patient comfort. The use of IUDs is increasing in the adolescent population, but perceived pain is a barrier to placement.\n\nPropofol is a commonly used agent for pediatric procedural sedation, but it has no analgesic properties. Ketorolac, a nonsteroidal anti-inflammatory drug, has been shown to reduce pain in adults and improve patient satisfaction when used prior to IUD placement..\n\nThe current study aims to determine if ketorolac, given in combination with propofol for IUD placement in adolescents, can improve comfort during placement and reduce pain following the procedure. Enrolled patients will receive ketorolac or placebo, in addition to propofol, for IUD placement. By comparing the outcomes of these two groups of patients, we can gain a better understanding of the optimal approach to sedation for IUD insertion in adolescents.",[565,566,567,568],"IUD","Healthy Female","Contraception","IUD Insertion Complication","2024-07-30",{"date":571,"type":31},"2024-07-31",{"date":573,"type":31},"2024-02-05",{"date":575,"type":22},"2025-06",{"name":37,"class":38},""]